Cefazolin Likely Superior, Safer Than Cloxacillin for MSSA

Cefazolin provides a safer and more effective treatment option for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia than cloxacillin or flucloxacillin.

A meta-analysis of two randomized clinical trials, which included approximately 1,600 patients, found that cefazolin is at least non-inferior and likely superior to the other drug classes.

The findings, published in a meta-analysis, suggest that cefazolin should be the preferred treatment for adults with this condition, according to Todd Lee, MD, MPH, of the Division of Infectious Diseases at McGill University and his colleagues. The researchers cited the drug’s longer half-life, better tolerability, and utility for patients with penicillin allergies as key advantages.

The meta-analysis evaluated data from the French Cloxacillin vs Cefazolin for MSSA Bacteremia (CloCeBa) trial and the International S aureus Network Adaptive Platform (SNAP) trial. These studies represent the first direct, large-scale comparisons of these two common antibiotic classes.

MSSA Treatment Update: Cefazolin Proven Non-Inferior and Potentially Safer — Updates in Infection

“Few questions in clinical infectious diseases have been debated for so long with so little reliable clinical data as the choice of ß-lactam for MSSA bacteremia,” Michihiko Goto, MD, MS, of the Center for Access & Delivery Research and Evaluation (CADRE) at the Iowa City VA Health Care System, remarked in an accompanying commentary, Contagion Live reported.

While both trials provided essential data, their methodologies differed regarding patient eligibility. The SNAP trial specifically enrolled patients with penicillin-resistant MSSA, whereas the CloCeBa trial included patients with MSSA regardless of their penicillin susceptibility.

Goto said that the CloCeBa trial demonstrated the noninferiority of cefazolin within a population that, theoretically, would have disadvantaged the drug. His analysis credits these randomized trials for resolving a long-standing uncertainty among clinicians regarding whether cefazolin remained at least as effective as traditional alternatives.

Did you know?

The CloCeBa trial included patients regardless of their penicillin susceptibility, whereas some clinical concerns historically focused on whether penicillin-resistant strains might impact the efficacy of cefazolin compared to cloxacillin.

The meta-analysis combined data from the CloCeBa and SNAP trials, encompassing a total of approximately 1,600 patients.

Yes, researchers identified that cefazolin has a longer half-life, is generally better tolerated by patients, and serves as an alternative for those with penicillin allergies.